SCHEMBL241253

SCHEMBL241253

CCCCN(C)S(=O)(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA1 P00915 5/20 0.38
CA12 O43570 2/20 0.38
CA9 Q16790 2/20 0.38
ALDH1A1 P00352 2/20 0.36
TP53 P04637 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP8 P22894 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
DNM1 Q05193 3/20 0.35
CA2 P00918 2/20 0.34
ALDH2 P05091 1/20 0.33
KDM5A P29375 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
S1PR2 O95136 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7518199 0.91 DNM1 (0.48) CA1CA12CA9DNM1CA2
SCHEMBL8211322 0.91 DNM1 (0.48) CA1CA12CA9DNM1CA2
SCHEMBL2588485 0.91 DNM1 (0.48) CA1CA12CA9DNM1CA2
SCHEMBL245936 0.84
SCHEMBL1035915 0.79 CA1 (0.43) CA1CA12CA9ALDH1A1TP53
SCHEMBL16090593 0.79 MEN1 (0.42) MEN1KMT2ACA1CA12CA9
SCHEMBL11989255 0.77 MEN1 (0.44) MEN1KMT2ACA1CA12CA9
SCHEMBL27564460 0.77 CA1 (0.42) CA1CA12CA9ALDH1A1TP53
Sulfuric Acid SCHEMBL20505719 0.77 DNM1 (0.55) CA1CA12CA9ALDH1A1TP53
SCHEMBL7108947 0.77 TDP1 (0.45) CA1CA12CA9ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105295631-A Fluorine-modified zinc acrylate antifouling coating material and preparation method thereof UNIV SHANGHAI 2016-02-03 CN claimed
US-11916195-B2 Electrolyte solution, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2024-02-27 US disclosed
US-20230387465-A1 COMPOUND, COMPOSITION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2023-11-30 US disclosed
US-20230145113-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, MODULE AND COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2023-05-11 US disclosed
US-20230129817-A1 ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2023-04-27 US disclosed
CN-110101708-A The non-operative treatment for treating cataract 密执安大学评议会 2019-08-09 CN disclosed
CN-104768615-B non-surgical method for treating cataract 密执安大学评议会 2019-02-22 CN disclosed
US-20160130230-A1 SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-05-12 US disclosed
CN-105295631-A Fluorine-modified zinc acrylate antifouling coating material and preparation method thereof UNIV SHANGHAI 2016-02-03 CN disclosed
US-9187428-B2 Substituted dicyanopyridines and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-11-17 US disclosed
EP-1221440-B1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators OTSUKA PHARMA CO LTD (JP) 2007-04-25 EP disclosed
CN-1727887-A Method for separating proteins by capillary electrophoresis and buffer compositions for capillary electrophoresis SEBIA SA (FR) 2006-02-01 CN disclosed
US-6642223-B2 A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2003-11-04 US disclosed
EP-1221440-A1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators Otsuka Pharmaceutical Company, Limited (JP) 2002-07-10 EP disclosed
US-20020049194-A1 Benzoheterocyclic derivatives OGAWA HIDENORI (JP) 2002-04-25 US disclosed
US-6335327-B1 Benzoheterocyclic derivatives OTSUKA PHARMACEUTICALS CO., LTD. (JP) 2002-01-01 US disclosed
US-6096735-A Benzoheterocyclic derivatives OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-08-01 US disclosed
EP-0765314-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-02 EP disclosed
WO-1995034540-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-12-21 WO disclosed
US-4231781-A Halophenoxy-alkoxy phosphonates and thiophosphonates GAF CORPORATION (US) 1980-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049194-A1 Benzoheterocyclic derivatives AVPR2, AVPR1A, AVPR1B MEN1 1227/4885KMT2A 4490/4885CA1 1348/4885
US-20160130230-A1 SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF QDPR, DPYD, DDC MEN1 2203/4885KMT2A 2205/4885CA1 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.